William Farnaby

The paper develops a NanoBRET assay to quantify intracellular GlyT1 target engagement in living cells, distinguishing intracellular from extracellular ligands and resolving structure-activity relationships.

The paper identifies a new mechanism of kinase inhibition through electrophilic modifications, revealing aspartate conjugation of ULK1 by a chloroacetamide warhead.

This study shows that frustration in the SMARCA2-VHL protein-protein interface correlates with PROTAC cooperativity, offering a framework for structure-based PROTAC design.

The paper introduces CRBNmidi, a Cereblon construct that enables high-resolution structural and biophysical studies of degraders without requiring DDB1 co-expression.

A single small molecule degrader targets 13 out of 17 prevalent oncogenic KRAS alleles, inhibiting growth of KRAS-driven cancer cell lines and inducing tumour regression in vivo.

This study shows that the natural half-life of a target protein significantly affects degradation by degrader agents and highlights confounding factors in screening for protein degraders.